Dramatic changes in the management of acute myocardial infarction (AMI) have occurred in the past decade. While previous management strategies were primarily supportive, current strategies focus on achieving and maintaining patency of the infarct-related artery restoring blood flow to jeopardized myocytes, preserving left ventricular function, and preventing recurrences and complications in addition to promoting healing. Resto out of bed with meals. Treatment with isosorbide dinitrate, 10 mg every 6 h, was begun. Premature ventricular contractions (35/h) were noted, and he was started on a regimen of quinidine gluconate, 324 mg orally every 8 h. Over the next 5 days he gradually increased his ambulation. A multiple gated acquisition scan showed an ejection fraction of 28%. A low-level exercise treadmill test on the tenth hospital day demonstrated no chest pain, arrhythmias, or ischemic ST segment changes.
He was discharged from the hospital on a regimen of digoxin, quinidine gluconate, isosorbide dinitrate, and furosemide. He was advised to start a cardiac rehabilitation program, avoid intimacy, and not to return to work for a 2-month period.
Six weeks later, he was hospitalized with congestive heart failure. Furosemide dosage was increased to 40 mg orally twice daily, and treatment with hydralazine, 25 mg orally every 6 h, was started. Twelve weeks after his initial hospitalization, he experienced a left hemispheric transient ischemic attack. Twodimensional echocardiography showed akinesis of the anterior wall and apex with a protruding apical thrombus. Warfarin therapy was begun. CASE HISTORY 1995 A 64-year-old man with a history of hypertension, tobacco use, and hypercholesterolemia presented with the new onset of 2 h of severe, substernal chest pain radiating to the left arm, shortness of breath, and diaphoresis. He appeared to be in moderate distress with a pulse of 104 beats/min, a blood pressure of 170/90 mm Hg, and a temperature of 37.3°C. There was a faint left carotid bruit, bibasilar rales, and an atrial gallop. The chest radiograph was normal.
The electrocardiogram revealed sinus tachycardia, first-degree atrioventricular block, and an evolving acute anterior wall myocardial infarction. Nitroglycerin, 0.4 mg, was given sublingually three times without relief of the chest pain. Tissue plasminogen activator and metoprolol were given intravenously; aspirin was given orally (chewed).
The patient was admitted to the coronary care unit where intravenous nitroglycerin and heparin therapy was begun. Ninety minutes later, the patient remarked that his chest discomfort had resolved, but he had begun to experience palpitations. Repeated electrocardiogram revealed almost complete resolution of the previous ST segment elevations; however, frequent multiform ventricular premature beats, ventricular couplets and triplets, and intermittent episodes of accelerated idioventricular rhythm at 72 beats/min were noted on telemetry. The patient's ventricular ectopy subsequently resolved without further therapy, and on the second hospital day he felt well enough to sit in a chair. He ambulated briefly on the third hospital day; an echocardiogram was done that showed overall normal left ventricular function with anteroapical and septal hypokinesis and a possible apical mural thrombus. Captopril and warfarin therapy was initiated with doses adjusted to therapeutic end points. Intravenous nitroglycerin therapy was discontinued. The patient continued cardiac rehabilitation. On the seventh hospital day, the patient underwent submaximal exercise testing on a modified Bruce protocol ambulating 9 min without chest pain or shortness of breath to a peak heart rate of 122 beats/min. On the eighth hospital day the patient was discharged from the hospital with metoprolol, warfarin, aspirin, and captopril for follow-up lipid and international normalized ratio testing by his local physician.
Regarding the current treatment of AMI: SET).5 These trials compared the intravenous thrombolytic agents streptokinase, anisoylated plasminogen streptokinase activator complex (APSAC), and rt-PA with placebo and showed a significant relative reduction in mortality ranging from 18 to 48%. Although these initial trials established the efficacy of these three thrombolytic agents, the trials also raised several important issues. These issues included patient selection criteria for treatment (especially with regard to advanced age and late presentation), use of adjunctive agents to enhance and maintain coronary artery patency, choice of thrombolytic agent, total dose of the agent, and the role of mechanical revascularization.
Initially, elderly patients were excluded from treatment because of the potential adverse effects, in particular, intracerebral hemorrhage.6 Most studies have shown a twofold increase in intracerebral hemorrhage in patients 70 years of age or older.7
However, the elderly also experienced a higher early mortality of 20 to 30% from AMI,8 suggesting that they have the greatest potential to benefit. Pooled data from the four previously mentioned trials showed a relative reduction in mortality of 18%.6 Therefore, patients experiencing AMI should be considered for thrombolytic therapy without an absolute age cutoff. However, in the 70 years and over age group, angioplasty in skilled hands is a proven alternative (see below).
The time dependency for reperfusion was suggested by experimental models of coronary ligation.9
In GISSI-1, streptokinase reduced mortality by 47% in patients receiving therapy within 1 h of symptoms onset, by 27% within >3 h, and by 20% between 3 and 6 h.2 The data strongly suggested a time cutoff where the benefits of thrombolysis would be outweighed by the risks. Nevertheless, in ISIS-2, patients receiving rt-PA within 12 h of symptom onset had a significant reduction in mortality, and those receiving rt-PA between 12 and 24 h enjoyed a reduction in mortality that approached statistical significance. presenting with symptoms suggestive of AMI and 1-mm ST segment elevation in two contiguous electrocardiogram leads who present within 24 h of symptom onset should be considered for thrombolytic therapy. For patients presenting in the 12-to 24-h time frame, a careful individualized analysis of risk-benefit ratio should be made. Contraindications to thrombolytic therapy include a history of cerebral vascular accident (especially hemorrhagic), intracranial neoplasm, arteriovenous malformation or aneurysm, bleeding diathesis, recent (within 2 months) intracranial, spinal, or major surgery at a noncompressible site, significant surgery within 2 weeks, uncontrolled hypertension, pericarditis, aortic dissection, and any active bleeding. The need for adjunctive agents to maintain recanalization achieved by thrombolytic therapy is emphasized by the high (10 to 30%) incidence of reocclusion and by a failure to initially achieve recanalization in 15 to 20% of patients despite the use of the most aggressive protocols.12" 3 A paradoxical state of thrombogenesis is induced by thrombolytic therapy that appears to be associated with both the activation of platelets and the coagulation cascade by the reexposure of blood to injured endothelium and thrombin in the residual thrombus.14 Therefore, adjunctive therapy combining antithrombotic agents and antiplatelet agents is rational.
Aspirin inhibits platelet aggregation by irreversibly acetylating cyclo-oxygenase, an enzyme required for the synthesis of thromboxane A2 (a potent stimulus of platelet aggregation, and subsequent thrombosis). In ISIS-2, aspirin alone resulted in a 23% reduction in mortality when compared with placebo. When aspirin was combined with streptokinase, there was a 42% reduction in mortality from AMI compared with placebo.3 Aspirin should be given early to all patients with AMI; the loading dose of aspirin is at least 160 mg. The role of heparin as an adjunctive therapy is less clear cut. In both GISSI-2 and ISIS-3, delayed subcutaneous heparin therapy did not improve survival and was associated with an increased incidence of bleeding.'15"6 Both trials have been criticized because the use of heparin was delayed17; to our knowledge, no trials of adequate size have demonstrated a mortality benefit of heparin. However, when using rt-PA, intravenous heparin appears important for maintaining early patency.18-20 Although the data are incomplete, American
College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend the immediate use of intravenous heparin and maintaining the partial thromboplastin time (PTT) at 2 to 21/2 times the control for 5 to 7 days.2' 2. a, b, c, and f Fibrin-selective agents, with a relative affinity for fibrin within clots such as rt-PA and prourokinase, were developed. These agents preferentially activate plasminogen within clots, without activating systemic plasminogen with the goal of achieving higher and faster rates of reperfusion while reducing bleeding complications.22 Studies have demonstrated that rt-PA results in higher early reperfusion rates than streptokinase.23'24 However, in GISSI-2, which compared streptokinase and rt-PA, and in ISIS-3, which compared streptokinase, APSAC, and rt-PA, there was no advantage in survival observed among the three fibrinolytic agents.'5"16 GISSI-2 and ISIS-3 were criticized because of the use of delayed subcutaneous heparin therapy that was believed to favor the nonfibrin-selective agents.
To address these issues, the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study compared streptokinase administered with subcutaneous heparin, streptokinase administered with intravenous heparin, combined rt-PA and streptokinase administered with intravenous heparin, and an accelerated dosage schedule of rt-PA with intravenous heparin.25 The latter schedule consisted of a 15-mg bolus of rt-PA, with two thirds of the conventional dose given in the first half hour and the remainder infused over the subsequent hour. This schedule had been shown to attain a remarkable 85% recanalization rate.26 In GUSTO, rt-PA was demonstrated to have a 14% greater survival benefit compared with the streptokinase regimens. Approximately 50% of the survival benefit was noted at 24 h, implying that early reperfusion was responsible for its advantage. Although an increased incidence of disabling hemorrhagic stroke was noted with rt-PA, for every 1,000 patients presenting with an AMI, there were 9 more survivors without disabling stroke in the rt-PA group. Furthermore, the favorable survival achieved by rt-PA compared with streptokinase was due to a superior 90-min patency rate (81% vs 54%).27 There were no significant differences in infarct-related artery patency rates among the four thrombolytic regimens after 3 h validating the open artery hypothe-sis that states that the beneficial effects of thrombolysis are due to myocardial salvage by early reperfusion. Nevertheless, some investigators have questioned the conclusion that rt-PA is the thrombolytic agent of choice because the survival advantage achieved with rt-PA, although significant, was small. Currently, no single thrombolytic protocol is considered to be ideal.28'29 3. c and d
At best, thrombolytic therapy restores the occluded artery to the diseased state that existed prior to intervention, leaving many patients at risk for reocclusion and recurrent ischemic events. Recurrent ischemia or infarction occurring early has been noted in 15 to 20% of patients after thrombolysis12 and may lead to dissipation of an early survival advantage at 1 year of follow-up.30 Noninvasive tomic improvement in the infarct-related arteries of the patients who underwent routine delayed PTCA after thrombolysis, there were no differences in mortality, reinfarction, or ejection fraction when compared with patients who underwent PTCA only for an ischemic end point. 35 In general, patients who have received thrombolytic therapy for AMI are referred for coronary angiography if they have spontaneous ischemia or inducible ischemia with noninvasive testing. Patients with congestive heart failure or significant left ventricular dysfunction due to previous infarction or a large current infarction are considered for coronary angiography on an individual basis.
Direct or primary PTCA without thrombolysis avoids the hemorrhagic complications of thrombolytics, and the severity of the underlying stenosis caused by the atherosclerotic plaque in the infarct-related artery is immediately reduced.36 In two trials, primary PTCA produced higher patency rates and less residual stenosis than thrombolysis, as well as reduced mortality, recurrent ischemia and infarction, and was associated with fewer hemorrhagic strokes.37 '38 In the trial conducted by the Primary Angioplasty in Myocardial Infarction Study Group, benefits were particularly evident in patients older than 70 years, in those with anterior infarctions, and .patients presenting with sinus tachycardia. A third trial found equivalent myocardial salvage with direct angioplasty and thrombolytics in AMI.39 Primary angioplasty can be applied only in the minority of hospitals in which the cardiac catheterization laboratory and surgical back-up can be rapidly mobilized. Even in these hospitals, primary angioplasty is logistically challenging. However, primary angioplasty is considered for patients who havi? absolute contraindications to thrombolytics, patients with symptoms suggestive of infarction and nondiagnostic electrocardiograms, patients with AMI and previous coronary artery bypass surgery, patients in cardiogenic shock or with anterior infarction or older than 70 years of age, those with persistent sinus tachycardia, and hospitalized patients with unstable angina who develop AMI. In summary, primary PTCA without antecedent thrombolysis and elective PTCA for an ischemic end-point after thrombolysis have therapeutic roles while immediate and routine delayed PTCA after thrombolysis do not.
c
Aspirin given during the initial stages of myocardial infarction exerts an independent beneficial effect on early mortality following myocardial infarction in patients whether they do or do not receive thrombolytics. In ISIS-2, 160 mg of aspirin given during the first 24 h of infarction reduced 30-day mortality by 23% and reinfarction by 49%. The survival benefits of aspirin as the sole agent were similar in magnitude to that seen with streptokinase alone.3 Aspirin may also be effective for secondary prevention in survivors of myocardial infarction; the benefits in secondary prophylaxis are more modest but relevant because of the large number of patients at risk. Of the six large randomized trials that evaluated aspirin in the secondary prevention of recurrent myocardial infarction and death, five studies showed a statistically nonsignificant trend for the reduction of mortality.40-44 One study showed aspirin to have a deleterious effect on mortality.45 A metaanalysis of antiplatelet therapy trials in secondary prevention after myocardial infarction revealed that aspirin therapy resulted in a 13% reduction in mortality and a 31% reduction in reinfarction rate. 46 The optimal dose of aspirin for treating myocardial infarction remains controversial despite exten- Heparin is also an important pharmacologic agent for the treatment of myocardial infarction in patients who are not candidates for thrombolytic therapy. The incidence of deep vein thrombophlebitis in patients with AMI is 17 to 38%. More than half of these episodes occur within 3 days of initial presentation. Congestive heart failure, shock, prolonged immobilization, and advanced age predispose to a higher incidence of thrombophlebitis. Full-dose heparin therapy was shown to be effective in preventing deep vein thrombophlebitis in the 1970s.51 Low-dose heparin therapy (5,000 U every 12 or every 8 h) acts by minor alterations in the coagulation cascade, and therefore, has the advantage of not increasing bleeding complications. The pooled results of three trials showed that low-dose heparin therapy, when begun early in patients with myocardial infarction, decreased the incidence of deep vein thrombophlebitis from 23 to 4%.51-54 Low-dose heparin therapy (5,000 U subcutaneously every 12 h) is routinely recommended for all patients with AMI for 48 h. High-risk patients with large infarctions, age older than 70 years, hemodynamic instability, obesity, history of venous disease, and prolonged immobilization require low-dose heparin therapy until fully ambulatory. Left ventricular thrombus and systemic arterial embolization are predominantly complications of anterior wall myocardial infarction.55 Most left ventricular thrombi form in the first few days following infarction. High-dose heparin (12,500 U subcutaneously every 12 h) administered early to patients with anterior infarctions reduced the incidence of ventricular thrombus from 32 to 11% in one study56 and from 37 to 18% in a second study.57 Accordingly, high-dose heparin administered either subcutaneously or intravenously is recommended for all patients with anterior wall Q-wave infarction for the duration of hospitalization. In patients who have left ventricular thrombi or large areas of akinesis in the apical anterior segment showed on two-dimensional echocardiography, warfarin therapy is recommended for the next 3 months. The pathogenesis of non-Qwave infarction and unstable angina is believed to be similar. Subtotal obstruction of a coronary artery or total occlusion followed by spontaneous recanalization and reperfusion can conceivably lead to both unstable coronary syndromes.58 Since 
In animal models of myocardial infarction, angiotensin converting enzyme (ACE) inhibitors prevented the progressive acute and chronic changes in ventricular geometry related to infarct size and hemodynamic stresses. Clinical trials showed that ACE inhibitors stopped progressive postinfarction left ventricular dilatation in patients with mildly to moderately depressed left ventricular function.74 In the Survival and Ventricular Enlargement trial, patients with a left ventricular ejection fraction of 40% or less, randomized 3 to 16 days postinfarction to receive captopril, showed a 25% risk reduction for allcause mortality compared with placebo. 75 The Acute Infarction Ramipril Efficacy study (AIRE) reported a 27% risk reduction in all-cause mortality for patients manifesting heart failure 3 to 10 days postinfarction randomized to ramipril (vs placebo).76
However, when intravenous enalapril was administered within the first 24 h of infarction in the Second Cooperative New Scandinavian Enalapril Survival Study (CONSENSUS II) trial, no difference was seen in 6-month mortality; hypotension noted in 25% of treated patients may have confounded the data.77
The question of early treatment was reinvestigated in the GISSI-3 trial in which patients were randomized to receive lisinopril, transdermal nitroglycerin, neither, or both within 24 h. Patients allocated to lisinopril therapy had an 11% 6-week mortality reduction (compared with placebo alone).78 As was noted in CONSENSUS II, treated patients were significantly more likely to have persistent hypotension and renal dysfunction, but this did not result in a change in overall mortality.
In the setting of AMI, intravenous nitroglycerin lowers left ventricular filling pressure, improves cardiac output, and improves regional myocardial ischemia as measured by precordial ST segment monitoring. The most beneficial hemodynamic effects are seen in patients with the most severe left ventricular failure. Randomized prospective trials of nitroglycerin therapy showed that treated patients evolved smaller infarcts and have a significant improvement in pooled end points of hospital death, infarct extension, and new congestive heart failure.79 Low-dose nitroglycerin infusion (without thrombolysis) for at least 48 h initiated within 10 h of myocardial infarction leads to statistically significant improvements in infarct size and ventricular remodeling that result in decreased risk for infarct extension, cardiogenic shock, left ventricular thrombus, and heart failure.
Three-month mortality was reduced by 25% in patients with anterior Q-wave infarct.80 The GISSI-3 trial examined nitroglycerin given intravenously for 24 h (with thrombolytics), then topically with a 10-h nitrate-free interval.'2 A small statistically insignificant benefit was seen in 6-week mortality. The combination of captopril and nitroglycerin did show a mortality benefit that was better than captopril alone. The ISIS-4 trial8' randomized 50,000 patients to receive captopril, magnesium, oral nitrates, or placebo within 24 h of confirmed or suspected myocardial infarction. Nitrates demonstrated a trend toward improved 35-day mortality, but this was not statistically significant.
Invariably, tachyphylaxis occurs after 24 h of continuous nitroglycerin administration independent of the route of delivery. Tachyphylaxis can be prevented by providing a 10-to 12-h nitroglycerinfree interval or in the case with continuous intravenous infusion, the dose is progressively increased every 12 h. The increases are regulated by the blood pressure response and headache tolerance.
The Secondary Prevention Reinfarction Trial (SPRINT)82 evaluated the calcium channel blocking agent nifedipine vs placebo 7 to 21 days after hospitalization. No difference was seen in 10-month mortality or recurrent nonfatal infarction. SPRINT 283 examined higher-risk patients with second or third infarctions randomizing within 3 h to nifedipine or placebo. In the 1,006 patients, 6-day and 6-month mortality was worsened in the nifedipine group. Diltiazem reduced 14-day reinfarction and refractory postinfarction angina rates after non-Q-wave myocardial infarction in patients treated 24 to 72 h after hospital admission.84 However, diltiazem did not show benefit on total mortality or nonfatal reinfarction in a larger study of patients with non-Qwave and Q-wave infarctions randomized 3 to 15 days after hospital admission. Subgroup analysis showed that the lack of overall benefit may have been accounted for by the increased cardiac event rate in patients with pulmonary congestion by chest radiograph or left ventricular ejection fraction <40% by radionuclide angiogram. On retrospective analysis, patients without either feature benefited from a decreased cardiac event rate.85 In the Danish Verapamil Infarction Trial (DAVIT) I, a trend toward improved survival and decreased reinfarction rate was seen in patients suspected of having myocardial infarction when randomized early to oral verapamil vs placebo therapy. Patients were excluded if they exhibited heart failure, heart block, or were receiving beta-blockers.86 DAVIT II examined verapamil use 2 weeks postinfarction and found a trend toward improved 18-month total mortality and reinfarction. Statistically significant improved survival was noted only in patients without heart failure (7.7% vs 11.8% in the verapamil and placebo groups, respectively).87
The studied benefits of early ambulation 3 to 5 days postmyocardial infarction became evident in the 1970s. Early ambulated patients clearly developed significantly fewer lower extremity venous thromboses even in the presence of heart failure. 88 Other advantages include prevention of cardiovascular deconditioning, enhancement of physical work capacity, and lessening of total disability. 89 The past fears of myocardial rupture and progressive failure were unfounded in that early ambulation has no detrimental effects on heart rate, left ventricular volume (remodeling), ejection fraction, or cardiac output when started 4 to 7 days after myocardial infarction. 90 Stress testing can assist in the evaluation of patients following AMI. ST segment depression on limited stress testing was shown to predict subsequent cardiac events.91 However, ST segment shifts in leads representing the potential electrical variations of the epicardial surface of areas that were not involved in the process of infarction are more predictive of future cardiac events. Exercise thallium 201 myocardial perfusion scanning is suggested in cases where the electrocardiogram is uninterpretable for ischemia. Thallium redistribution, thallium defects in more than one vascular territory, and lung uptake are more sensitive for predicting cardiac events (death, recurrent infarction, or severe angina) than angiography or stress testing alone.92 Failure of the left ventricular ejection fraction to increase by 5% on radionuclide ventriculography is 95% sensitive (compared with 54% for electrocardiographic changes) for cardiac events.93 More recently, reversible thallium defects post-Q-wave myocardial infarction have been shown to be 75% sensitive and 51% specific for future cardiac events, whereas angina or ST depression was 40% sensitive and had a positive predictive value of only 17%. Importantly, the negative predictive value for thallium scintigraphy was 89%.94 Despite this, other recent reports have suggested that stress testing after thrombolysis is less sensitive in predicting future adverse cardiac events. A symptom-limited modified Bruce protocol used 7 to 21 days after infarction, with over 10 months of follow-up, showed that only ST depression at <7 METS or inability to perform >7 METS discriminated for future cardiac events. ST depression at >7 METS or angina was not predictive. Combining all abnormal exercise tests, sensitivity for future cardiac events was 83% but specificity was 25%. Again the negative predictive value of a normal stress test was 89%. 95 Studies conducted in the 1960s and 1970s confirmed the premise that cholesterol was an important risk factor for coronary heart disease events after myocardial infarction. The Coronary Drug Project96 examined in a double-blind, randomized, placebocontrolled fashion the effect of lipid-lowering therapy of men surviving myocardial infarction. In 5 years of follow-up, elevated cholesterol level was positively associated with worsened total and cardiac mortality and recurrent nonfatal infarction; triglycerides were not specifically correlated. A meta-analysis of secondary prevention trials showed that serum cholesterol level lowering (via drug or diet) by 10% was associated with a 19% reduction in recurrent nonfatal infarction and a 12% reduction in fatal infarction. Angiographic studies have demonstrated over a 1-to 2-year period nonprogression and even regression of coronary lesions (although of a minor absolute degree) with currently available aggressive cholesterol level-lowering agents. Most marked in these studies was a decrease in acute event rates.
Most Q-wave myocardial infarctions and sudden cardiac deaths have been related to rupture of the fibrous cap of a susceptible plaque leading to overlying thrombus formation. These susceptible plaques are more lipid laden and are paradoxically minimally or moderately occlusive. It The rapid rise of health-care costs in the last 15 years has spawned research in risk stratification postmyocardial infarction with special attention to length of hospital stay and appropriate guidelines for early discharge from the hospital. Risk factors such as ventricular tachycardia or fibrillation, supraventricular tachycardia, postinfarct angina, infarct extension, pulmonary edema, or cardiogenic shock have identified a poorer prognosis, the need for more invasive investigation, and a longer hospital stay. In a risk assessment model, the risk of death, cardiogenic shock, or cardiac arrest was assessed during the 2-week period following proposed hospital discharge. By this model, 47% of the patients could be discharged from the hospital after 5 days with <2% risk of adverse outcome.101 A group of patients after uncomplicated (no angina, heart failure, or arrythmia) infarction without provocable ischemia on exercise testing discharged from the hospital on day 3 (vs day 7 to 10) showed no difference in readmission, reinfarction, or angina and the total hospital bill was approximately $5,000 less. Nearly all of the patients had received thrombolytics, angioplasty, or both. However, only 15% of screened patients qualified for randomization. Therefore, simple clinical variables can identify a proportion of patients suitable for early hospital discharge (day 3 to 5); however, this proportion appears to be low.102 
